ANTIMICROBIAL RESISTANCE SOLUTIONS
WITH DR. JOHN H. REX
Latest Newsletters
Latest Government Action





















R&D Insight
Can you help?
Antimicrobial resistance poses a catastrophic threat. If we don’t act now, any one of us could go into hospital in 20 years for minor surgery and die because of an ordinary infection that can’t be treated by antibiotics. And routine operations like hip replacements or organ transplants could be deadly because of the risk of infection.
Dame Sally Davies Tweet


















New pipeline analysis: Cancer projects were funded 17x more than antibacterials during 2011-2020
IDSA White Paper on developing narrow-spectrum antimicrobials + editorial by G. Drusano
Modeling the value of an effective antibiotic — Megiddo et al.
Push! Pull! Push! Pull! / Highlights from Davos 2018
FDA Workshop: Animal models in support of narrow-spectrum agents for A. baumannii and P. aeruginosa
The hunt for oral antibiotics: Beyond Lipinski’s Rule of Five
FDA and EMA regulatory updates / Fireside chat during the 4th AMR Conference
What does an antibiotic cost to develop? What is it worth? How to afford it?
Developing systemic & inhaled antibiotics for lung infections
News from Davos 2020: Some positive signs, but overall a fragile antibiotic market at a tipping point
New mechanisms for antibiotic reimbursement in the United States: CMS’s IPPS FY2020 Final Rule
Global survey of novel antibiotic reimbursement models / PASTEUR Act introduced to US House
The thoughtless person playing with penicillin treatment is morally responsible for the death of the man who succumbs to infection with the penicillin-resistant organism.
Alexander Fleming Tweet

The bipartisan PASTEUR Act is the strongest bill ever written to strengthen antibiotic development and use. It will fix our market failures, expand the pipeline for next generation antibiotics, and save lives. We can’t sit on our hands as this public health crisis arrives – we have to act now.
U.S. Senator Michael Bennet Tweet